 |
EinNewswires: Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics” December 2022 | |
|
EinNewswires: Paras Biopharma Creates Excellence with Continuous Biomanufacturing -Achieves objectives of High Productivity Innovation. December 2022 | |
 |
PR.com/Benzinga: Paras Biopharmaceuticals is Highly Recommended for Biologics CDMO – Development, Scale-up & Production - November 2022 | |
|
EinNewswires: Paras Biopharmaceuticals is Highly Recommended for Biologics CDMO – Development, Scale-up & Production - November 2022 | |
|
EinNewswires: Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market worth $ 2.60 billion by 2030. Key players in this market includes Paras Biopharmaceuticals – September 2022 | |
 |
DelveInsight: Rich Insights into the Robust Osteoporosis Clinical Trials Pipeline Analysis. Key Osteoporosis companies include Paras Biopharmaceuticals. August 2022 | |
|
Delveinsight: Key Osteoporosis companies such as Paras Biopharmaceuticals, and others, are evaluating new osteoporosis drugs candidate to improve the treatment landscape. August 2022 | |
 |
Nordic Life Science: “In Oulu, Finland, Paras Biopharmaceuticals has also started offering an expanded and increased biologics CDMO capacity to biopharmaceutical companies, beginning in March this year. 2022 | |
 |
BioSpace News Report: “In February 2019, Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim.” Jun 13, 2022 | |
 |
Newswires News Report: “Paras Biopharmaceuticals Finland Oy – Exploring Reverse Merger Opportunity” May 03, 2022 | |
 |
Finance News Report: “Ranibizumab Biosimilars Market Research 2022: Comprehensive Insights About 17+ Companies and 17+ Marketed and Pipeline Drugs - ResearchAndMarkets.com” February 14, 2022 | |
 |
InsightAce Analytic: The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market worth $ 635.9 million by 2028 - Exclusive Report where The prominent players in the Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing industry include Paras Biopharmaceuticals Finland. January 2022 | |
 |
Pr Newswire News Report: “The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market worth $ 635.9 million by 2028 - Exclusive Report by InsightAce Analytic” Jan 25, 2022 | |
 |
News Report: Named as “One of the Top Pharma Outsourcing Companies in Europe 2021” | |
 |
Insulin Glargine Biosimilar Insight Report: 2020 Report Insulin Glargine Biosimilars Pipeline Drugs 2021” | |
 |
News Report: Pipeline Review on Post-Menopausal Osteoporosis Metabolic Disorders pipeline landscape. 2021 | |
 |
InsightAce Analytic Pvt. Ltd: Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Assessment 2021 | |
 |
Outlook India Magazine An Outlook Initiative with DigiLive Inspiring Business Leaders 2021 | |
 |
Biosimilar Insulin Market Research Report 2021 Elaborate Analysis with Growth Forecast To 2027. Top Companies in this report include Paras Biopharmaceuticals | |
 |
Insulin biosimilar market 2021-2027: Growth analysis, CAGR status, market size, trends, growth prospects, types and in-depth qualitative insights. Leading manufacturers in the biosimilar insulin market including Paras Biopharmaceuticals Finland Oy | |
|
Global Postmenopausal Osteoporosis Market Nsights: Challenges and New Trends 2021 - Leading Players inc., Paras Biopharmaceutical Finland Oy | |
 |
MarketInsights Reports Top Companies in the Global Biosimilar Insulin Market including Paras Biopharmaceuticals Finland Oy | |
 |
2021 Biosimilar Insulin Sales Market Report- Recent Trends, Market Growth and Opportunities: Biosimilar Insulin Sales Market Research Report created by Report Consultant | |
 |
Competitor Analysis Medical and Health Markets: Postmenopausal Osteoporosis Market 2021: Global industry analysis report to 2027 | |
 |
Competitor Analysis Biosimilar Insulin Market: Top vendors, upcoming trends, sales, revenue and profit margin, market size analysis to forecast period 2021-2027 | |
 |
Competitor Analysis: The Global Post Menopause Osteoporosis Market report features an in-depth analysis on the market development. | |
 |
Data Bridge Market Research: Postmenopausal Osteoporosis Market to Register a Strong Growth Rate and Huge Profits, USA, 2021 | |
|
Research Report: Biosimilar Insulin Market Prominent Growth by Clinical Aspect, Highlights and Key Developments, USA, 2021 | |
 |
Data Intelo Market Research: Biosimilar Insulin Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis, USA, 2021 | |
 |
Competitor Analysis Report: Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Growing Vigorously Among Top Key Players, USA, 2021 | |
 |
Competitor Analysis: Finland Advanced Facilities Analysis Market Informative Data: Trends, Challenges & Drivers 2021-2027, USA, 2021 | |
 |
Competitor Analysis: Global Biosimilar Insulin Market Segmentation, Growth Drivers, Market Size and Trends – 2021 – 2027, USA/UK, 2021 | |
|
InsightAce Analytic: Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Assessment – Industry Analysis, Clinical Trial/pipeline Analysis, COVID 19 Impact Analysis and Revenue Forecast Till 2028, India, 2020 | |
 |
News Report:Romiplostim Biosimilar to Begin Comparative Clinical Trials in 2019 | |
 |
Press Release: 2019 BIO International Convention Exhibitor, USA, 2019 | |
 |
Research and Markets - Osteoporosis/OA: Companies that are the most active within the pipeline for osteoporosis and OA therapeutics: Skeletal Disease Drug Development Pipeline Review 2017 | |
 |
Competitor Analysis:Paras Biopharmaceuticals to raise EUR 10m - EUR 20m with a view to mid-term IPO, MergerMarket, UK, 2014 | |
 |
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies, Research and Markets, Ireland, 2014 | |
 |
Type 2 Diabetes:Pipeline Review, Global Market Direct, USA, 2014 | |
|
Metastatic Prostate Cancer: Pipeline review, Research and Markets, Ireland, 2014 | |
|
Post Menopausal Osteoporosis: Pipeline review, Global Market Direct, USA, 2014 | |
|
Competitor Analysis Report: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors, Research and Markets, Ireland, 2013 |
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.
